AtaiBeckley's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 72.83.
AtaiBeckley's Days Inventory for the
three
months ended in Mar. 2026 was .
AtaiBeckley's Days Payable for the
three
months ended in Mar. 2026 was .
Therefore, AtaiBeckley's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 72.83.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
AtaiBeckley Cash Conversion Cycle Related Terms
AtaiBeckley Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for AtaiBeckley's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:B72 vs GLUE, NUVB, BHVN: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, AtaiBeckley's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtaiBeckley Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AtaiBeckley's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where AtaiBeckley's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
AtaiBeckley's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtaiBeckley (STU:B72) has a Cash Conversion Cycle of 72.83 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on AtaiBeckley and its competitors.
Is AtaiBeckley's Cash Conversion Cycle too high?
AtaiBeckley's current Cash Conversion Cycle is 72.83. The Biotechnology industry median Cash Conversion Cycle is 102.38. AtaiBeckley's value of 72.83 is 28.9% below this industry median. Overall, AtaiBeckley has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does AtaiBeckley's Cash Conversion Cycle compare to GLUE and NUVB?
AtaiBeckley's Cash Conversion Cycle of 72.83 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.38. AtaiBeckley's value of 72.83 is 28.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.38, based on 875 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtaiBeckley's current Cash Conversion Cycle of 72.83 is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on AtaiBeckley and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtaiBeckley's current Cash Conversion Cycle is 72.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtaiBeckley stock overvalued right now?
AtaiBeckley (STU:B72) has a current Cash Conversion Cycle of 72.83. The stock's GF Value™ is €6.32, compared to a current price of €3.45 — trading 45.5% below its estimated fair value. The current Cash Conversion Cycle is 72.83 and 28.9% below the Biotechnology industry median of 102.38. AtaiBeckley's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For AtaiBeckley (STU:B72), the current Cash Conversion Cycle is 72.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtaiBeckley (STU:B72) Overvalued in 2026?
Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued.
The current stock price of €3.45 is trading 45.5% below its estimated GF Value™ of €6.32.
Key valuation signals for STU:B72:
Cash Conversion Cycle: 72.83
GF Value™: €6.32 vs. price of €3.45 (45.5% below fair value)
Industry Position: 28.9% below the Biotechnology median
No single metric tells the full story. See the STU:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
51GF Score
Get the complete analysis for STU:B72
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:B72 has been successfully added to your 
